Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

Abstract Background Ovarian cancer is the leading cause of cancer-related death among women. Complete cytoreductive surgery followed by platinum-taxene chemotherapy has been the gold standard for a long time. Various compounds have been assessed in an attempt to combine them with conventional chemot...

Full description

Bibliographic Details
Main Authors: Kuo-Chang Wen, Pi-Lin Sung, Alexander T. H. Wu, Ping-Chieh Chou, Jun-Hung Lin, Chi-Ying F. Huang, Sai-Ching J. Yeung, Mong-Hong Lee
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Journal of Ovarian Research
Subjects:
Neoadjuvant metformin
Ovarian cancer
Clinically relevant dosage
AKT/mTOR pathway
Synergistic effects
Online Access:http://link.springer.com/article/10.1186/s13048-020-00703-x

Internet

http://link.springer.com/article/10.1186/s13048-020-00703-x

Similar Items